佐力药业(300181) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders of the listed company reached ¥11,185,144.83, an increase of 227.04% year-on-year[9]. - Operating revenue for the reporting period was ¥228,263,754.94, representing a growth of 67.00% compared to the same period last year[9]. - Basic earnings per share for the reporting period were ¥0.0184, up 226.90% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥9,595,964.71, reflecting a 196.91% increase compared to the previous year[9]. - Net profit for the period was ¥9,795,915.18, compared to a net loss of ¥6,306,546.99 in the previous period, marking a turnaround in profitability[53]. - The company's total profit for the current period was ¥11,829,429.33, compared to a loss of ¥14,759,199.17 in the previous period, marking a significant recovery in overall financial performance[60]. - The net profit for the current period was ¥31,906,955.84, up 45.4% from ¥21,979,213.68 in the previous period[73]. Cash Flow - The net cash flow from operating activities increased by 283.23% to ¥52,702,076.31 year-to-date[9]. - Net cash flow from operating activities was $52,702,076.31, a significant improvement compared to a net outflow of $28,763,473.24 in the previous period[80]. - The company reported a total cash outflow from operating activities of $598,662,548.19, slightly lower than $609,901,060.38 in the previous period[80]. - Cash inflow from sales of goods and services was $322,888,618.44, an increase from $307,996,243.60 in the prior period[85]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,089,045,413.32, a decrease of 1.17% compared to the end of the previous year[9]. - Total current assets decreased to ¥765,320,615.31 from ¥888,351,023.97, a decline of approximately 13.9% year-over-year[37]. - Total liabilities decreased to ¥666,428,374.12 from ¥726,501,127.31, a reduction of approximately 8.3%[39]. - The company's total equity increased to ¥1,422,617,039.20 from ¥1,387,302,366.08, an increase of about 2.5%[41]. - Short-term borrowings at the end of the reporting period were CNY 226.50 million, a decrease of 32.85% compared to the beginning of the period, reflecting changes in loan structure[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,359[15]. - The largest shareholder, Yu Youqiang, holds 28.46% of the shares, amounting to 173,187,284 shares, with a portion pledged[15]. Operating Costs and Expenses - Total operating costs amounted to ¥226,481,162.76, up from ¥157,951,447.16, indicating an increase of about 43%[51]. - Research and development expenses were ¥5,809,660.12, down from ¥6,375,728.13, showing a decrease of approximately 9%[51]. - The company’s sales expenses increased to ¥114,822,210.07 from ¥71,184,480.86, representing an increase of approximately 61%[51]. Investment and Other Income - The company reported non-operating income of ¥4,305,237.28 from government subsidies closely related to business[11]. - The company reported other income of ¥8,831,689.61, which is an increase from ¥8,306,935.69 in the previous period, indicating stable additional revenue streams[58]. - The company experienced a loss in investment income of ¥293,339.16, contrasting with a gain of ¥5,386,550.53 in the previous period[73]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[73].